American Superconductor Corporation vs Centene Corp — how do they compare? American Superconductor Corporation trades at $32.66 (market cap $1.50B), while Centene Corp trades at $65.58 (market cap $32.89B). The key difference: Centene Corp is far larger — about 21.9× American Superconductor Corporation's market cap, and Centene Corp is trading nearer its 52-week high, American Superconductor Corporation nearer its low. Which is the better fit depends on your goals.
| AMSC | CNC | |
|---|---|---|
Market Cap | $1.50B | $32.89B |
Sector | Technology | Health |
52-Week High | $66.68 | $68.72 |
52-Week Low | $25.95 | $26.17 |
Enterprise Value | $1.36B | $21.93B |
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $32.77, down 0.41% with bearish technical signals including RSI overbought conditions and negative cash flow trends. The company reported strong revenue growth of 30% year-over-year in Q1 2026 to $94.1 million but faces margin pressure, with earnings missing estimates. Record orders above $130 million and a $400 million backlog provide visibility, though valuation metrics show mixed signals with a reasonable P/E of 10.06 but elevated EV/EBITDA of 63.13.
Outlook remains cautiously optimistic given strong order pipeline and exposure to energy infrastructure growth, particularly in grid solutions and data center markets. Key risks include margin compression from cost pressures and execution challenges in integrating recent growth. Analyst consensus leans bullish with 53% buy ratings, but investors should monitor Q3 earnings delivery and cash flow improvement for sustained upside.
Centene (CNC) trades at $65.77, up 2.48% with a bullish technical signal. Recent Q2 2026 earnings beat expectations with EPS of $2.51 versus $1.09 estimate, driven by margin recovery and cost control. Revenue grew to $194.78B in 2025, though net income was negative at -$6.67B. Valuation ratios are attractive with P/E of 8.06 and P/S of 0.16. Analyst consensus is strongly bullish with 61.37% buy ratings and a $70.36 price target.
Outlook is positive due to raised 2026 guidance and operational improvements, but risks include Medicaid membership softness and persistent negative margins. The stock offers value potential if profitability rebounds as projected, though investors should monitor medical cost trends and regulatory changes affecting government healthcare programs.
Trailing returns across standard periods
Latest headlines on both assets
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →